Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 11, Novembre 2015
Page(s) 964 - 967
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153111009
Publié en ligne 17 novembre 2015
  1. Cuvillier O. Les récepteurs de la sphingosine 1-phosphate : de la biologie à la physiopathologie. Med Sci (Paris) 2012 ; 28 : 951–957. [CrossRef] [EDP Sciences] [PubMed]
  2. Cuvillier O, Ader I, Bouquerel P, et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010 ; 3 : 53–65. [CrossRef] [PubMed]
  3. Newton J, Lima S, Maceyka M, Spiegel S Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res 2015 ; 333 : 195–200. [CrossRef] [PubMed]
  4. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006 ; 9 : 225–238. [CrossRef] [PubMed]
  5. Ponnusamy S, Selvam SP, Mehrotra S, et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012 ; 4 : 761–775. [CrossRef] [PubMed]
  6. Brizuela L, Martin C, Jeannot P, et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol Oncol 2014 ; 8 : 1181–1195. [CrossRef] [PubMed]
  7. Semenza GL Hypoxia-inducible factors in physiology and medicine. Cell 2012 ; 148 : 399–408. [CrossRef] [PubMed]
  8. Hasmim M, Messai Y, Noman MZ, Chouaib S L’hypoxie tumorale : un déterminant clé de la réactivité stromale et de la réponse antitumorale. Med Sci (Paris) 2014 ; 30 : 422–428. [CrossRef] [EDP Sciences] [PubMed]
  9. Ceze N, Lecomte T, Watier H Anticorps monoclonaux thérapeutiques et ciblage vasculaire. Med Sci (Paris) 2009 ; 25 : 1099–1104. [CrossRef] [EDP Sciences] [PubMed]
  10. Azzi S, Gavard J Vaisseaux sanguins et tumeurs ou l’art du dialogue. Med Sci (Paris) 2014 ; 30 : 408–414. [CrossRef] [EDP Sciences] [PubMed]
  11. Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011 ; 10 : 417–427. [CrossRef] [PubMed]
  12. Gothié E, Pouyssegur J HIF-1: régulateur central de l’hypoxie. Med Sci (Paris) 2002 ; 18 : 70–78. [CrossRef] [EDP Sciences]
  13. Ader I, Brizuela L, Bouquerel P, et al. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 2008 ; 68 : 8635–8642. [CrossRef]
  14. Sodhi A, Montaner S, Miyazaki H, Gutkind JS MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 2001 ; 287 : 292–300. [CrossRef] [PubMed]
  15. Lappano R, Maggiolini M G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011 ; 10 : 47–60. [CrossRef] [PubMed]
  16. Ader I, Gstalder C, Bouquerel P, et al. Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer. Oncotarget 2015 ; 6 : 13803–13821. [CrossRef] [PubMed]
  17. Mucci LA, Powolny A, Giovannucci E, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009 ; 27 : 5627–5633. [CrossRef] [PubMed]
  18. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001 ; 7 : 1932–1936. [PubMed]
  19. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003 ; 4 : 133–146. [CrossRef] [PubMed]
  20. Jain RK Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001 ; 7 : 987–989. [CrossRef] [PubMed]
  21. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012 ; 72 : 402–407. [CrossRef]
  22. Emblem KE, Mouridsen K, Bjornerud A, et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 2013 ; 19 : 1178–1183. [CrossRef] [PubMed]
  23. Treps L, Gavard J L’angiogenèse tumorale : quand l’arbre de vie tourne mal. Med Sci (Paris) 2015 ; 31 : 989–995. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.